Regeneron to defend US Justice Department's complaint on drug-pricing manipulation-March 2024-www.financetom.com

Regeneron to defend US Justice Department's complaint on drug-pricing manipulation

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Regeneron to defend US Justice Department's complaint on drug-pricing manipulation

Apr 15, 2024 5:33 PM

April 15 (Reuters) - Regeneron Pharmaceuticals ( REGN )

said on Monday the U.S. Justice Department's complaint against

the company misreporting the average sales price for its macular

degeneration drug Eylea is "meritless" and it plans to defend

this case in court.

The Justice Department last week had accused Regeneron of

manipulating Medicare's drug-pricing process by inflating the

average sales price for its Eylea drug.

Previous page： Ascendis Pharma Reports 45% Clinical Response in TransCon IL-2 Phase 1/2 Trial Next page： Cytokinetics Insider Sold Shares Worth $635,978, According to a Recent SEC Filing

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Ascendis Pharma Reports 45% Clinical Response in TransCon IL-2 Phase 1/2 Trial

Jun 3, 2024

04:34 PM EDT, 06/03/2024 (MT Newswires) -- Ascendis Pharma ( ASND ) said Monday that 45% of patients with locally advanced or metastatic solid tumors getting TransCon IL-2 every three weeks in the phase 1/2 clinical trial showed clinical response. The company said as of the April 16 data cutoff, two of the five patients with anti-PD-1 refractory melanoma in...

Cytokinetics Insider Sold Shares Worth $635,978, According to a Recent SEC Filing

Jun 3, 2024

04:36 PM EDT, 06/03/2024 (MT Newswires) -- Robert Wong, Vice President, Chief Accounting Officer, on June 03, 2024, sold 13,011 shares in Cytokinetics ( CYTK ) for $635,978. Following the Form 4 filing with the SEC, Wong has control over a total of 16,653 shares of the company, with 16,653 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1061983/000112760224017303/xslF345X03/form4.xml ...

Salesforce Insider Sold Shares Worth $3,371,314, According to a Recent SEC Filing

Jun 3, 2024

04:35 PM EDT, 06/03/2024 (MT Newswires) -- Marc Benioff, Director, Chair and CEO, on May 31, 2024, sold 15,000 shares in Salesforce ( CRM ) for $3,371,314. Following the Form 4 filing with the SEC, Benioff has control over a total of 22,392,327 shares of the company, with 12,392,327 shares held directly and 10,000,000 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1108524/000112760224017304/xslF345X03/form4.xml Price:...

GitLab Swings to Non-GAAP Earnings in Fiscal Q1 as Sales Climb; Q2, FY Guidance Set

Jun 3, 2024

04:37 PM EDT, 06/03/2024 (MT Newswires) -- GitLab ( GTLB ) reported fiscal Q1 non-GAAP earnings late Wednesday of $0.03 per diluted share, compared with a loss of $0.06 a year earlier. Analysts polled by Capital IQ expected a loss of $0.04. Revenue in the quarter ended April 30 rose to $169.2 million, up from $126.9 million a year earlier....